Crewe Advisors’s Aspire Biopharma ASBP Stock Holding History

Crewe Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.62K	Sell	677 -1	-0.1%	-$10	﹤0.01%	927
2026 Q1	$20.9K	Hold	678	–	–	﹤0.01%	508
2025 Q4	$107K	Hold	678	–	–	0.01%	277
2025 Q3	$168K	Buy	678 +156	+30%	+$78.1K	0.02%	231
2025 Q2	$169K	Buy	522 +261	+100%	+$124K	0.02%	174
2025 Q1	$183K	Buy	+261	New	+$1.8M	0.03%	145

Other funds holding ASBP

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Crewe Advisors's ASBP Position: Q2 2026 in Review

Crewe Advisors reduced its Aspire Biopharma (ASBP) stake by 0.15% in Q2 2026, selling an estimated $10 and leaving 677 shares worth $3.62K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Crewe Advisors first reported a position in ASBP in Q1 2025 and has held it in 6 quarters since. The position peaked at $183K in Q1 2025. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

Crewe Advisors held 677 shares of Aspire Biopharma worth $3.62K as of Q2 2026.
Crewe Advisors sold 1 Aspire Biopharma share in Q2 2026, an estimated $10.
Aspire Biopharma made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #927 holding.
Crewe Advisors first reported a position in Aspire Biopharma in Q1 2025 and has held it in 6 quarters since.
Crewe Advisors's Aspire Biopharma position peaked at $183K in Q1 2025.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.